Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2026 Open access

Read full text
Authors: Tiffany Chen, Grace Kim, Yekta Rahimi, Monisha Kamdar, Eduardo Fernandez-Hernandez, Karrune Woan, Eric L. Tam, George Yaghmour
DOI: 10.32604/or.2025.072443
Cited by: 4

Abstract

m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several other agents in development, ziftomenib (KO-539), bleximenib (JNJ-75276617), and icovamenib (BMF-219). We also focused our discussion on future directions to include resistance mechanisms, biomarker identification and monitoring strategies, and combination therapies. Menin inhibition is now being clinically integrated into relapsed/refractory and frontline treatment settings.

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments Microtubule and mitosis dynamics

Publication details

Journal / source
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Publisher
Tech Science Press
Volume
34
Issue
3
Pages
1–10
Publication date
1 January 2026
Language
EN